Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Several Prostate Cancer Drug Candidates Heading Into Home Stretch

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010.

You may also be interested in...

Circulating Tumor Cell Detection A Technology To Watch In 2009 – Cleveland Clinic

Technology offers more rapid feedback on metastatic cancer progression than imaging or tumor-localized biomarker tests, clinic says.

Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX

Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.

Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On

Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts